{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-315039","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2025-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.865354+00:00","generated_at":"2026-05-16T13:30:09.665276+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Corbus posts Phase 1a data for CRB-913: weight loss signal, no serious AEs; Phase 1b started","bullets":["Phase 1a SAD/MAD of oral CB1 inverse agonist CRB-913 (n=112) showed no serious AEs, no GI intolerability, no neuropsychiatric events except mild anxiety/irritability in obese cohort.","In obese MAD cohort (150 mg QD), all 9 CRB-913-treated participants lost weight; mean placebo-adjusted 2.9% loss at Day 14 (range 1.3-4.3%).","Initiated Phase 1b CANYON-1 (12-week, 240 obese non-diabetic participants, doses 20/40/60 mg); completion expected summer 2026.","PK profile supports once-daily dosing; no suicidality, depression, or insomnia reported across all study cohorts."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-315039","json":"https://secwatch.observer/filing/0001193125-25-315039.json","markdown":"https://secwatch.observer/filing/0001193125-25-315039.md","text":"https://secwatch.observer/filing/0001193125-25-315039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000119312525315039/0001193125-25-315039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000119312525315039/crbp-20251211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:30:09.665276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}